- Trial phase
- Preclinical / entering Phase 1
- Time to market
- ORKA-004 has not yet entered clinical trials. Assuming Phase 1 starts in late 2026 or early 2027, a potential approval would likely be 5-8 years away, if clinical development is successful.
- Why 3/10
- ORKA-004 has no hard dated catalyst in the next ~12 months. It was expected to enter clinical development in Q4 2026 (per Q2 2026 guidance), but no specific start date, PDUFA, or pivotal readout is scheduled. The company's value is overwhelmingly driven by lead asset ORKA-001 (Phase 2b/3).
Watch for an announcement that ORKA-004 has entered clinical development (expected Q4 2026 per prior guidance). The more impactful near-term catalysts for ORKA stock are the 52-week EVERLAST-A data for ORKA-001 due December 2026 and ORKA-002 Phase 2 data due Q1 2027. ORKA-004 is a pipeline-extender, not a near-term value driver.
Price Chart
Executive Summary
ORKA-004 is a preclinical-stage half-life extended monoclonal antibody targeting TL1A, being developed by Oruka Therapeutics (NASDAQ: ORKA) for inflammatory bowel disease (IBD). It was expected to enter clinical development in Q4 2026, though no formal announcement of first dosing has been made as of November 9, 2026. ORKA-004 is a pipeline-extending asset; Oruka's primary value driver is ORKA-001, a Phase 2b IL-23p19 inhibitor for psoriasis that has shown best-in-class efficacy. The company holds $1.2B in cash and plans Phase 2 combination studies of ORKA-004 with its other assets starting in 2027. For a non-medical investor, ORKA-004 is too early-stage to be a meaningful standalone catalyst for the stock.
How It Works
ORKA-004 is a half-life extended monoclonal antibody that blocks TL1A, a protein involved in triggering inflammation in the gut. By neutralizing TL1A, the drug aims to reduce the inflammatory cascade that drives inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis. The 'half-life extended' design means the drug may stay active in the body longer, potentially allowing less frequent dosing.
Trial Status
ORKA-004 was expected to enter clinical development in Q4 2026 per the company's Q2 2026 corporate update. No first-patient-dosed or IND clearance announcement has been made as of November 9, 2026. The company plans to initiate Phase 2 combination studies with ORKA-001 and ORKA-002 beginning in 2027.
The Two-Sided Case
Upcoming Catalysts
- Entry into clinical development (IND clearance / first patient dosed) - expected Q4 2026, not yet announced
- Phase 2 combination studies with ORKA-001 and ORKA-002 - planned for 2027
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Oruka Therapeutics, Inc. PRESS-RELEASE ORKA ·Originating report